Breaking News

Inovio Appoints Quality VP

April 1, 2014

Brandreth to head quality and compliance functions for clinical trials

E.J. Brandreth has been appointed vice president of Quality at Inovio Pharmaceuticals, Inc. Mr. Brandreth will be responsible for all quality and compliance functions for clinical trials and scaling up manufacturing and other operations to support the company’s pipeline of immunotherapies and DNA vaccines. He reports to Inovio's chief operating officer, Dr. Niranjan Sardesai.
 
Prior to joining Inovio, Mr. Brandreth had a successful career transitioning start-up clinical biotech operations into commercial entities, and supported the growth of several pharma companies in quality and compliance areas. Most recently, he served as senior vice president of Quality and Regulatory Affairs at Ajinomoto Althea, and previously held similar positions with IDEC, BioMarin and Favrille, Inc.

Related Compliance:

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research